ReviewPharmaceutics2022
Selenium-Containing Agents Acting on Cancer-A New Hope?
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Selenium-Containing 1,4-Naphthoquinone Derivatives Trigger Reactive Oxygen Species and Apoptosis in Triple-Negative Breast Cancer Cells.Drug development research · 2026Article
- Challenges and Opportunities for Cleavable Linkers Used in Polymer-Drug Conjugates.Journal of the American Chemical Society · 2026Review
- Development of a multi-targeted sulfonyl-bridged bisselenadiazole derivative as a potent EGFR/PI3K/AKT/mTOR modulator in lung adenocarcinoma.RSC advances · 2026Article
- Selective Cytotoxicity of Sodium Enone Salts Through Mitochondrial Dysfunction and Cell Cycle Arrest in Human Cancer Cells.Molecules (Basel, Switzerland) · 2026Article
- Anticancer selenopeptides from food sources: synthesis strategies and multitarget mechanisms.iScience · 2026Review
- WRKY transcription factors govern selenium metabolism in Broussonetia papyrifera: genome-wide identification, expression profiling, and regulatory network analysis.BMC plant biology · 2026Article
- Combining Gold and Selenium as Emerging Bioactive Compounds: From Synthesis to Therapeutic Potential.ACS omega · 2026Review
- Article
- Preclinical Investigation of PLGA Nanocapsules and Nanostructured Lipid Carriers for Organoselenium Delivery: Comparative In Vitro Toxicological Profile and Anticancer Insights.Pharmaceutics · 2025Article
- The selenium paradox friend or foe in breast cancer?Annals of medicine and surgery (2012) · 2025Review
- Responsive Organoselenium Dendritic Polymers: From Monodisperse Dendrimers to Self-Assembled Micelles for Advanced Therapeutic Applications.Journal of the American Chemical Society · 2025Article
- New Fluorescent Chemodosimetric Mechanism for Selective Recognition of Selenocysteine by Dansyl-Appended Ruthenium Nitrosyl Complexes.Inorganic chemistry · 2025Article
- Mechanism-Based Inhibition of Histone Deacetylase 6 by a Selenocyanate Is Subject to Redox Modulation.Journal of the American Chemical Society · 2025Article
- Article
- Mechanism-Based Inhibition of Histone Deacetylase 6 by a Selenocyanate is Subject to Redox Modulation.bioRxiv : the preprint server for biology · 2025Article
- The Potential of Integrative Cancer Treatment Using Melatonin and the Challenge of Heterogeneity in Population-Based Studies: A Case Report of Colon Cancer and a Literature Review.Current oncology (Toronto, Ont.) · 2024Review
- Antioxidant Metabolism Pathways in Vitamins, Polyphenols, and Selenium: Parallels and Divergences.International journal of molecular sciences · 2024Review
- First-in-Class Selenium-Containing Potent Serotonin Receptor 5-HTJournal of medicinal chemistry · 2024Article
- PLGA and PDMS-basedFrontiers in pharmacology · 2024Article
- Antiproliferative Effect of Inorganic and Organic Selenium Compounds in Breast Cell Lines.Biomedicines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Selenium-containing agents are more and more considered as an innovative potential treatment option for cancer. Light is shed not only on the considerable advancements made in understanding the complex biology and chemistry related to selenium-containing small molecules but also on Se-nanoparticles. Numerous Se-containing agents have been widely investigated in recent years in cancer therapy in relation to tumour development and dissemination, drug delivery, multidrug resistance (MDR) and immune system-related (anti)cancer effects. Despite numerous efforts, Se-agents apart from selenocysteine and selenomethionine have not yet reached clinical trials for cancer therapy. The purpose of this review is to provide a concise critical overview of the current state of the art in the development of highly potent target-specific Se-containing agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.